Laboratory for the Research of Neurodegenerative Diseases, VIB Center for Brain and Disease Research, 3000, Leuven, Belgium.
Leuven Brain Institute, KU Leuven, 3000, Leuven, Belgium.
Acta Neuropathol. 2024 Jun 9;147(1):96. doi: 10.1007/s00401-024-02747-5.
Although apoptosis, pyroptosis, and ferroptosis have been implicated in AD, none fully explains the extensive neuronal loss observed in AD brains. Recent evidence shows that necroptosis is abundant in AD, that necroptosis is closely linked to the appearance of Tau pathology, and that necroptosis markers accumulate in granulovacuolar neurodegeneration vesicles (GVD). We review here the neuron-specific activation of the granulovacuolar mediated neuronal-necroptosis pathway, the potential AD-relevant triggers upstream of this pathway, and the interaction of the necrosome with the endo-lysosomal pathway, possibly providing links to Tau pathology. In addition, we underscore the therapeutic potential of inhibiting necroptosis in neurodegenerative diseases such as AD, as this presents a novel avenue for drug development targeting neuronal loss to preserve cognitive abilities. Such an approach seems particularly relevant when combined with amyloid-lowering drugs.
虽然细胞凋亡、细胞焦亡和铁死亡与 AD 有关,但没有一种能够完全解释 AD 大脑中广泛的神经元丢失。最近的证据表明,细胞坏死在 AD 中大量存在,细胞坏死与 Tau 病理学的出现密切相关,并且坏死标记物在颗粒空泡变性神经退行性变小泡(GVD)中积累。在这里,我们回顾了颗粒空泡介导的神经元坏死途径的神经元特异性激活,该途径上游的潜在 AD 相关触发因素,以及坏死体与内溶酶体途径的相互作用,可能为 Tau 病理学提供联系。此外,我们强调了抑制神经退行性疾病(如 AD)中细胞坏死的治疗潜力,因为这为开发针对神经元丢失以维持认知能力的药物提供了新途径。当与降低淀粉样蛋白的药物结合使用时,这种方法似乎尤为相关。